Announcements
Sidley Represents Star51 Capital in Its Investment in UltraSight’s US$24 Million Financing
September 25, 2026
Sidley represented Star51 Capital in connection with its investment in UltraSight™, a leader in AI-guided cardiac workflows, as part of the company’s US$24 million Series B2 financing. The financing was led by Alive HealthTech Growth Fund, with additional participation from Deep Insight, Connecticut Innovations, and eHealth Ventures, as well as existing investors Mayo Clinic Ventures, New York University, and Iron Nation. UltraSight™ intends to use the proceeds to support its U.S. commercial expansion, develop new workflows for intensive care and circulatory support settings, and pursue strategic collaborations to expand adoption of its Echosystem platform.
The Sidley team was led by Mayan Katz (Emerging Companies and Venture Capital).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Cymphony in Its US$30 Million Series A FinancingSeptember 18, 2026When the Meeting Minutes and the AI Transcript Don’t Match: Litigation Insights From Delaware ChancerySeptember 17, 2026Sidley Represents Noetive in US$41 Million Series Seed FinancingSeptember 17, 2026Sidley Represents Verily Health in Investment from NVIDIASeptember 11, 2026The Evolving Regulatory Landscape for Private Credit: Key Considerations for LendersSeptember 3, 2026Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private PlacementAugust 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
